Ukraine Help: The heroes of Mainz-Finthen
Travis Kelley helps Olena and Wasyl flee from Ukraine. This is the record of a dramatic and emotional rescue operation.
Search
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
Generalized pustular psoriasis: Value of community support
Dr Clerisme-Beaty and Dr Strober MD, PhD discuss the importance of knowledge sharing, community support and challenges faced by those living with GPP.
Prof. Eric Haaksma
Prof. Eric Haaksma on transforming lives for generations
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
The Boehringer Ingelheim Veterinary Scholars Program
The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
A professional family
We believe that great teams are made up of people who are happy, fulfilled and have a sense of purpose. Flexibility and work/life balance are highly valued.
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Phase 1 start for novel triple agonist obesity treatment
Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
Mexico rabies free dog vaccination campaigns
Mexico: a champion in the fight against rabies. The first country in the world to be declared free from dog-transmitted rabies.
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Knowing the enemy: PRRS and PCVD
The swine industry is constantly vigilant of viruses such as PRRS and PCV2 (PCVD). Learn about prevention, symptoms knowledge, and control measures to make a difference.
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA